| HOME >> BIOLOGY >> TECHNOLOGY |
Deferred revenue 202 (3,975)
Deferred income tax 794 645
Deferred rent (88) (87)
Deferred compensation plan liabilities 544 593
Net cash provided by operating activities 71,181 72,041
Investing activities:
Proceeds from sales and maturities of short-term
investments 57,391 83,641
Purchases of short-term investments (182,449) (104,163)
Purchases of property, plant and equipment (17,674) (40,126)
Capitalization of intangible assets, including
license and manufacturing access fees (2,127) (2,245)
Cash paid for investment in Qualigen - (6,993)
Other assets (334) (223)
Net cash used in investing activities (145,193) (70,109)
Financing activities:
Repurchase and retirement of restricted stock for
payment of taxes (1,020) -
Excess tax benefit from employee stock options 13,055 8,232
Proceeds from issuance of common stock 40,677 19,089
Net cash provided by financing activities 52,712 27,321
Effect of exchange rate changes on cash and cash
equivalents 283 485
Net (decrease)/increase in cash and cash
equivalents (21,017) 29,738
Cash and cash equivalents at the beginning of
period 87,905 32,328
Cash and cash e
'/>"/>
| SOURCE Gen-Probe Incorporated Copyright©2007 PR Newswire. All rights reserved |